Endocrine Pathology

, 2:123 | Cite as

Effect of treatment with octreotide on the morphology of growth hormone—secreting pituitary adenomas: Study of 24 cases

  • Albert Beckers
  • Kalman Kovacs
  • Eva Horvath
  • Roger Abs
  • Michel Reznik
  • Achille Stevenaert
Original Article


Twenty-four acromegalic patients were treated with octreotide subcutaneously for periods of 3 to 6 weeks (group I, 12 cases) or 6 months (group II, 12 cases) before transsphenoidal surgery. Radiological studies performed in 19 patients before and at the end of this treatment period revealed no changes in 8 cases. In 8 other cases, a slight reduction in tumorsize was observed, and in 3 cases an important shrinkage was documented. At surgery, the adenomatous tissue appeared softer than in nonpretreated patients, facilitating the operation. Pathological examination revealed widening of perivascular spaces with accumulation of fibrous tissue and more crinophagy than in nonpretreated patients but failed to reveal morphologically pronounced cell involution as observed in prolactin-producing adenomas treated with dopamine agonists. No significant difference in frequency or extent of cellular changes was noted between the two groups. These morphological findings seem to be more consistent with a functional inhibition of growth hormone release than with cellular alterations induced by octreotide.


Adenoma Octreotide Pituitary Adenoma Acromegaly Secretory Granule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Asa SL, Scheithauer BW, Bilbao JM, Horvath E, Ryan N, Kovacs K, Randall RV, Laws ER, Singer W, Linfoot JA, Thorner MO, Vale W. A case for hypothalamic acromegaly: a clinical study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab 58:796–803, 1984.PubMedGoogle Scholar
  2. 2.
    Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. Treatment of acromegaly with the longacting somatostatin analog SMS 201-995. J Clin Endocrinol Metab 66:16–23, 1988.PubMedGoogle Scholar
  3. 3.
    Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040–1048, 1988.PubMedCrossRefGoogle Scholar
  4. 4.
    Barnard LB, Grantham WG, Lamberton P, O’Dorisio TM, Jackson IM. Treatment of resistant acromegaly with long-acting somatostatin analogue (SMS 201-995). Ann Intern Med 105:856–861, 1986.PubMedGoogle Scholar
  5. 5.
    Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Press J. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140, 1983.CrossRefGoogle Scholar
  6. 6.
    Besser GM, Mortimer CH, Carr D, Schally AV, Coy DH, Evered D, Kastin AJ, Turnbridge WMG, Thorner MO, Hall R. Growth hormone release inhibiting hormone in acromegaly. Br Med J 1:352–355, 1974.PubMedGoogle Scholar
  7. 7.
    Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, del Pozo E. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 64:447–453, 1987.PubMedGoogle Scholar
  8. 8.
    Comi RJ, Gorden P. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab 64:37–42, 1987.PubMedGoogle Scholar
  9. 9.
    Ducasse MCR, Tauber JP, Tourre A, Bonafe A, Babin TH, Tauber MT, Harris AG, Bayard F. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 65:1042–1046, 1987.PubMedGoogle Scholar
  10. 10.
    George SR, Kovacs K, Asa SL, Horvath E, Cross EG, Burrow GN. Effect of SMS 201-995, a long acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma. Clin Endocrinol (Oxf) 26:395–405, 1987.CrossRefGoogle Scholar
  11. 11.
    Guiot G, Oproiu A, Hertzog E, Fredy D. Adénomes hypophysaires. EMC Paris 17:340, 1969.Google Scholar
  12. 12.
    Kovacs K, Horvath E. Tumors of the pituitary gland. In: Atlas of tumor pathology, second series, fascicle 21. Washington, DC: Armed Forces Institute of Pathology, 1986, pp 1–269.Google Scholar
  13. 13.
    Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60:1161–1165, 1985.PubMedGoogle Scholar
  14. 14.
    Lamberts SWJ, Uitterlinden P, Verschoor L, Van Dongen KJ, del Pozo E. Longterm treatment of acromegaly with the somatostatin analogue SMS 202–995. N Engl J Med 313:1576–1580, 1985.PubMedGoogle Scholar
  15. 15.
    Lamberts SWJ, Zweens M, Verschoor L, del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine and the combination of both drugs. J Clin Endocrinol Metab 3:16–19, 1986.Google Scholar
  16. 16.
    Landolt AM, Osterwalder V. Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 8:1179–1183, 1984.Google Scholar
  17. 17.
    Landolt AM, Osterwalder V, Stuckrnann G. Preoperative treatment of acromegaly with SMS 201–995: surgical and pathological observation. In: Ludecks DK, Tolis G, eds. Growth hormone, growth factors and acromegaly. New York: Raven Press, 1987, pp 229–244.Google Scholar
  18. 18.
    Scheithauer BW, Kovacs K, Randall RV, Horvath E, Okazaki H, Laws ER Jr. Hypothalamic neuronal hamartoma and adenohypophyseal neuronal choristoma: their association with growth hormone adenoma of the pituitary. J Neuropathol Exp Neurol 2:648–663, 1983.CrossRefGoogle Scholar
  19. 19.
    Spinas GA, Zapf J, Landolt AM, Stuckmann G, Froesch ER. Preoperative treatment of 5 acromegalics with somatostatin analogue: endocrine and clinical observations. Acta Endocrinol (Copenh) 14:249–256, 1987.Google Scholar
  20. 20.
    Sternberger LA, Hardy PH, Cuculis J, Meyer HG. The unlabeled antibody enzyme method of immunochemistry. Preparation and properties of soluble antigen-antibody complex (horseradish peroxydase anti-horseradish peroxidase) and its use in the identification of spirochetes. J Histochem Cytochem 8:315–333, 1970.Google Scholar
  21. 21.
    Tindall GT, Kovacs K, Horvath E, Thorner MO.Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 5:1178–1183, 1982.Google Scholar
  22. 22.
    Vezina JL, Maltais R. La selle turcique dans l’acromégalie. Etude radiologiquc. Neurochir-urgic 9(suppl2):35, 1973.Google Scholar

Copyright information

© Humana Press Inc. 1991

Authors and Affiliations

  • Albert Beckers
    • 1
  • Kalman Kovacs
    • 4
  • Eva Horvath
    • 4
  • Roger Abs
    • 5
  • Michel Reznik
    • 2
  • Achille Stevenaert
    • 3
  1. 1.Department of EndocrinologyCHU, University of LiègeBelgium
  2. 2.Department of PathologyCHU, University of LiègeBelgium
  3. 3.Department of NeurosurgeryCHU, University of LiègeBelgium
  4. 4.Department of Pathology, St. Michael’s HospitalUniversity of TorontoCanada
  5. 5.Department of EndocrinologyUniversity of AntwerpBelgium

Personalised recommendations